RxDoctor Payments Data

Matthew Dickson, MD

Otolaryngology/Facial Plastic Surgery · Glens Falls, NYNPI 1528021706

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Acclarent, Inc at 27.2% of the total.

$6,960in general payments, 2019–2025

Across 173 payments — averaging $40.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acclarent, Inc$2K
  • Intersect ENT, Inc.$1K
  • Inspire Medical Systems, Inc.$899
  • Integra Lifesciences Corporation$790
  • GSK$457
  • Sanofi$382
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$3255%
  • Food & beverage$6,63595%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,960 in reported general payments places this provider in the 75th percentile of 48 otolaryngology/facial plastic surgery providers in New York.

See all otolaryngology/facial plastic surgery providers in New York

Medicare billing

Part B allowed, 2024
$61,286
Medicare patients
307
Services billed
841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Arnuity ElliptaFluticasone Furoate14$3,527
Fluticasone Propionate150$1,921
Ipratropium Bromide47$1,673
Ofloxacin34$1,399
Azelastine Hcl39$1,155
Fluocinolone Acetonide Oil21$707
Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort12$507
Montelukast Sodium76$474
Amitriptyline Hcl19$256
Omeprazole36$234
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$107
Prednisone17$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArnuity Ellipta$457$3,52714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 48 otolaryngology/facial plastic surgery providers in New York.

Other otolaryngology/facial plastic surgery in Glens Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →